National and Kapodistrian University of Athens
Νέοι λακταμικοί στεροειδείς αλκυλιωτές αναστολείς των PARP-1/PARP-2 για τη στοχευμένη θεραπεία του καρκίνου των ωοθηκών
Abstract
dc:descriptionThe purpose of this dissertation is to investigate the antitumor potential of some innovative and newly synthesized homo-aza-steroid derivatives against ovarian cancer cells. Ovarian cancer is one of the most common causes of death in the female population. Currently, the usual treatment includes surgery and a combination of platinum/ taxane chemotherapy. However, the treatment proves ineffective for a high percentage of patients, due to the emergence of drug resistance in many chemotherapeutic procedures. Therefore, it is critical to develop new therapeutic approaches, capable of bypassing any chemo-resistance, and at the same time optimizing the effectiveness of the treatment, while reducing the drug toxic effects. Inherited mutations in the BRCA1 and BRCA2 genes have been associated with an increased risk of ovarian cancer. These genes are involved in DNA repair, through homologous recombination and double-stranded repair of the genetic material (DNA). PARPs, with an emphasis on the predominant PARP-1 and PARP-2 (approximately 80% of all the functionalitiy), are protein molecules that participate in a variety of biochemical processes and molecular pathways. One of them is a second key repair mechanism, the single-strand DNA repair, which takes place mainly in BRCA-deficient cells, involving the activity of PARP-1/2 enzymes. Cancer cells with such a dysfunction, are an excellent target for pharmaceutical use of PARP enzyme inhibitors, as repair is bypassed and cell death occurs. The methodology of the present research dissertation includes two experimental approaches: The first one concerns the in silico design, the evaluation of the ADMET properties and of the PARP inhibitory potential of the tested compounds through molecular docking, but also the chemical synthesis of the new compounds found efficient/ competent through the above procedures. The second approach is focused on the evaluation of the compounds’ biological activity in vitro and on a molecular level, through MTT, ELISA and PCR, in terms of cytotoxicity, inhibition of PARP and their transcriptional effects respectively. The novel studied molecules take a structure of a hybrid-lactam steroid derivative, conjugated to an alkylator, i.e. toxic molecule that cause DNA damage. The results of this study indicate that they are indeed anti-cancer agents, with specific cytotoxic activity mostly against cancer cells. They present both reduced toxicity and significant inhibitory effect on PARP-1 and PARP-2 proteins, at the same time.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Nikoleousakos, Nikolaos
- Νικολεουσάκος, Νικόλαος
Subjects
dc:subject × 31- Καρκίνος ωοθηκών
- Υβριδικοί λακταμικοί στεροειδείς αλκυλιωτές
- Αναστολείς PARP1/ PARP2
- Συνθετική θνησιμότητα
- Ανακάλυψη φαρμάκων
- Αντικαρκινικοί παράγοντες
- Αντινεοπλασματική δράση
- BRCA1/2
- Ovarian cancer
- ANTICANCER ALKYLATING AGENTS
- Lactam esters
- PARP-1
- PARP1/ PARP2 inhibitors
- Synthetic lethality
- Anticancer drugs
- Antineoplasmatic
- Drug discovery
- Anticancer activity
- Anticancer agents
- steroid derivatives
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Φαρμακολογία και Φαρμακευτική
- Ανακάλυψη και Ανάπτυξη φαρμάκων
- Άλλες Ιατρικές Επιστήμες
- Ιατρική έρευνα και Πειραματική ιατρική
- Basic Medicine
- Medical and Health Sciences
- Pharmacology and Pharmacy
- Other Medical Sciences
- Research and Experimental medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/52141